BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23290583)

  • 1. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
    Caponi S; Vasile E; Funel N; De Lio N; Campani D; Ginocchi L; Lucchesi M; Caparello C; Lencioni M; Cappelli C; Costa F; Pollina L; Ricci S; Mosca F; Falcone A; Boggi U
    Eur J Surg Oncol; 2013 Apr; 39(4):396-403. PubMed ID: 23290583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
    Otsuka T; Morizane C; Nara S; Ueno H; Kondo S; Shimada K; Kosuge T; Ikeda M; Hiraoka N; Okusaka T
    Pancreas; 2013 Jul; 42(5):889-92. PubMed ID: 23695798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
    Lucocq J; Hawkyard J; Haugk B; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; Van Laarhoven S; Robertson F; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Søreide K; Pandanaboyana S
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38659247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
    Swartz MJ; Hsu CC; Pawlik TM; Winter J; Hruban RH; Guler M; Schulick RD; Cameron JL; Laheru DA; Wolfgang CL; Herman JM
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):839-44. PubMed ID: 19647950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
    Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
    Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.
    Yogi T; Hijioka S; Imaoka H; Mizuno N; Hara K; Tajika M; Tanaka T; Ishihara M; Shimizu Y; Hosoda W; Yatabe Y; Niwa Y; Yoshimura K; Bhatia V; Fujita J; Yamao K
    J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.
    Hwang DW; Jang JY; Lee SE; Lim CS; Lee KU; Kim SW
    Langenbecks Arch Surg; 2012 Jan; 397(1):93-102. PubMed ID: 20640860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
    Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of aggressive surgery for an invasive carcinoma derived from an intraductal papillary mucinous neoplasm diagnosed preoperatively as borderline resectable.
    Aimoto T; Mizutani S; Kawano Y; Suzuki H; Uchida E
    J Nippon Med Sch; 2013; 80(5):371-7. PubMed ID: 24189355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas.
    Mimura T; Masuda A; Matsumoto I; Shiomi H; Yoshida S; Sugimoto M; Sanuki T; Yoshida M; Fujita T; Kutsumi H; Ku Y; Azuma T
    J Clin Gastroenterol; 2010 Oct; 44(9):e224-9. PubMed ID: 20453661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.
    Nakajima Y; Yamada T; Sho M
    Surg Today; 2010 Sep; 40(9):816-24. PubMed ID: 20740343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
    Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance.
    Kang MJ; Jang JY; Lee KB; Chang YR; Kwon W; Kim SW
    Ann Surg; 2014 Aug; 260(2):356-63. PubMed ID: 24378847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.